vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Guardian Pharmacy Services, Inc. (GRDN). Click either name above to swap in a different company.
Guardian Pharmacy Services, Inc. is the larger business by last-quarter revenue ($336.6M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 2.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.
ESPR vs GRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $336.6M |
| Net Profit | — | $13.5M |
| Gross Margin | — | 22.7% |
| Operating Margin | 50.6% | 5.3% |
| Net Margin | — | 4.0% |
| Revenue YoY | 143.7% | 2.2% |
| Net Profit YoY | — | 46.1% |
| EPS (diluted) | $0.32 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.6M | ||
| Q4 25 | $168.4M | $397.6M | ||
| Q3 25 | $87.3M | $377.4M | ||
| Q2 25 | $82.4M | $344.3M | ||
| Q1 25 | $65.0M | $329.3M | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | $314.4M | ||
| Q2 24 | $73.8M | — |
| Q1 26 | — | $13.5M | ||
| Q4 25 | — | $20.9M | ||
| Q3 25 | $-31.3M | $9.8M | ||
| Q2 25 | $-12.7M | $9.0M | ||
| Q1 25 | $-40.5M | $9.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-122.0M | ||
| Q2 24 | $-61.9M | — |
| Q1 26 | — | 22.7% | ||
| Q4 25 | — | 21.5% | ||
| Q3 25 | — | 19.8% | ||
| Q2 25 | — | 19.8% | ||
| Q1 25 | — | 19.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | — |
| Q1 26 | — | 5.3% | ||
| Q4 25 | 50.6% | 7.7% | ||
| Q3 25 | -11.4% | 4.3% | ||
| Q2 25 | 8.6% | 3.7% | ||
| Q1 25 | -34.0% | 3.9% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | -33.3% | ||
| Q2 24 | 3.5% | — |
| Q1 26 | — | 4.0% | ||
| Q4 25 | — | 5.3% | ||
| Q3 25 | -35.9% | 2.6% | ||
| Q2 25 | -15.4% | 2.6% | ||
| Q1 25 | -62.2% | 2.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -38.8% | ||
| Q2 24 | -83.9% | — |
| Q1 26 | — | $0.21 | ||
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $64.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $232.4M |
| Total Assets | $465.9M | $426.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.9M | ||
| Q4 25 | $167.9M | $65.6M | ||
| Q3 25 | $92.4M | $36.5M | ||
| Q2 25 | $86.1M | $18.8M | ||
| Q1 25 | $114.6M | $14.0M | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | $37.2M | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $0 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $34.3M | ||
| Q2 24 | — | — |
| Q1 26 | — | $232.4M | ||
| Q4 25 | $-302.0M | $217.9M | ||
| Q3 25 | $-451.4M | $195.5M | ||
| Q2 25 | $-433.5M | $179.7M | ||
| Q1 25 | $-426.2M | $163.2M | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | $133.9M | ||
| Q2 24 | $-344.2M | — |
| Q1 26 | — | $426.9M | ||
| Q4 25 | $465.9M | $412.7M | ||
| Q3 25 | $364.0M | $390.0M | ||
| Q2 25 | $347.1M | $356.3M | ||
| Q1 25 | $324.0M | $334.0M | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | $348.0M | ||
| Q2 24 | $352.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $6.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 0.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $6.1M | ||
| Q4 25 | $45.2M | $34.6M | ||
| Q3 25 | $-4.3M | $28.2M | ||
| Q2 25 | $-31.4M | $19.9M | ||
| Q1 25 | $-22.6M | $17.6M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | — | ||
| Q2 24 | $-7.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $24.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | 0.45× | ||
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 1.86× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GRDN
Segment breakdown not available.
